Human DNA ligase III
AssigneeHuman Genome Sciences, Inc.
InventorsYing-Fei Wei, Guo-Liang Yu, William A. Haseltine
Life of this patent
Estimating the term…
Abstract
A human DNA Ligase III polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide via gene therapy for the treatment of disorders associated with a defect in DNA Ligase III. Antagonists against such polypeptides and their use as a therapeutic to destroy unwanted cells are also disclosed. Diagnostic assays to detect mutant DNA Ligase III genes are also disclosed.
Claims49
An antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of:
- (a) amino acids 1 to 922 of SEQ ID NO:2;
- (b) amino acids 2 to 922 of SEQ ID NO:2;
- (c) an antigenic fragment of the amino acid sequence of SEQ ID NO:2;
- (d) amino acids 1 to 922 of SEQ ID NO:2, wherein the amino acid sequence has one to five conservative substitutions;
- (e) at least 30 contiguous amino acid residues of SEQ ID NO:2;
- and
- (f) at least 50 contiguous amino acid residues of SEQ ID NO:2.
A hybridoma cell line that produces a monoclonal antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of:
- (a) amino acids 1 to 922 of SEQ ID NO:2;
- (b) amino acids 2 to 922 of SEQ ID NO:2;
- (c) an antigenic fragment of the amino acid sequence of SEQ ID NO:2;
- (d) amino acids 1 to 922 of SEQ ID NO:2, wherein the amino acid sequence has one to five conservative substitutions;
- (e) at least 30 contiguous amino acid residues of SEQ ID NO:2;
- and
- (f) at least 50 contiguous amino acid residues of SEQ ID NO:2.
An antibody or portion thereof produced by immunizing an animal with a protein whose sequence consists of an amino acid sequence selected from the group consisting of:
- (a) amino acids 1 to 922 of SEQ ID NO:2;
- (b) amino acids 2 to 922 of SEQ ID NO:2;
- (c) an antigenic fragment of the amino acid sequence of SEQ ID NO:2;
- (d) amino acids 1 to 922 of SEQ ID NO:2, wherein the amino acid sequence has one to five conservative substitutions;
- (e) at least 30 contiguous amino acid residues of SEQ ID NO:2;
- and
- (f) at least 50 contiguous amino acid residues of SEQ ID NO:2;
- wherein said antibody or portion thereof specifically binds to said protein.
An antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of:
- (a) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (b) the full-length protein, excluding the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (c) a mature protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (d) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052, wherein the amino acid sequence has one to five conservative substitutions;
- (e) an antigenic fragment of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (f) at least 30 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- and
- (g) at least 50 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052.
A hybridoma cell line that produces a monoclonal antibody or portion thereof that specifically binds to a protein whose sequence consists of an amino acid sequence selected from the group consisting of:
- (a) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (b) the full-length protein, excluding the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (c) a mature protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (d) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052, wherein the amino acid sequence has one to five conservative substitutions;
- (e) an antigenic fragment of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (f) at least 30 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- and
- (g) at least 50 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052.
An antibody or portion thereof produced by immunizing an animal with a protein whose sequence consists of an amino acid sequence selected from the group consisting of:
- (a) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (b) the full-length protein, excluding the N-terminal methionine, encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (c) a mature protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (d) the full-length protein encoded by the human cDNA contained in ATCC Deposit No. 97052, wherein the amino acid sequence has one to five conservative substitutions;
- (e) an antigenic fragment of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- (f) at least 30 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- and
- (g) at least 50 contiguous amino acid residues of a protein encoded by the human cDNA contained in ATCC Deposit No. 97052;
- wherein said antibody or portion thereof specifically binds to said protein.
Dependencies are inferred from the claim text.